The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
132
Ophthalmic suspention; QID
Ophthalmic suspension; QID
ophthalmic suspension vehicle; QID
Unnamed facility
Inglewood, California, United States
Unnamed facility
Torrance, California, United States
Unnamed facility
Bloomfield, Connecticut, United States
Unnamed facility
Indianapolis, Indiana, United States
Total fluorescein corneal staining
Time frame: 8 weeks
Ocular Symptom Severity
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
New Albany, Indiana, United States
Unnamed facility
Gretna, Louisiana, United States
Unnamed facility
Bangor, Maine, United States
Unnamed facility
Cleveland, Ohio, United States
Unnamed facility
Philadelphia, Pennsylvania, United States
Unnamed facility
San Antonio, Texas, United States